+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Treatment - Resistant Depression (TRD) - Epidemiology Forecast - 2028

  • ID: 4845160
  • Report
  • September 2019
  • Region: Global
  • 91 pages
  • DelveInsight
1 of 2
‘Treatment-Resistant Depression (TRD) - Epidemiology Forecast - 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Treatment-Resistant Depression in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period:2017-2028

Treatment-Resistant Depression - Disease Understanding

The European Union's Committee for Human Proprietary Medicinal Products (CHMP)'s defines TRD as: ‘A patient is considered therapy-resistant (TRD) when consecutive treatments with two different antidepressant products, used for a sufficient length of time at an adequate dose with adequate affirmation of treatment adherence, fail to induce a clinically meaningful improvement.'
Adults with TRD bear a heavy burden of disease. According to recent literature reviews, adults with TRD as compared with those with treatment-responsive depression tend to have longer episodes of depression, more previous psychiatric hospital admissions, higher symptom severity, and a greater risk of comorbid anxiety disorders. Various symptoms experienced by children include Guilt, feeling of emptiness, self-dislike, sense of failure, self-denigration, quality of mood, fears and phobias, suicidal attempts, etc.

Treatment-Resistant Depression - Epidemiology

The Treatment-Resistant Depression epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Age-Specific Prevalence) scenario of Treatment-Resistant Depression in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to this report, the total prevalent cases of Treatment-Resistant Depression (TRD) in the 7MM was found to be 8,339,329 in 2017. The prevalence of Treatment-Resistant Depression in the 7MM is expected to increase during the study period of 2017 to 2028.

Among 7MM, the United States has the highest prevalent population of Treatment-Resistant Depression with about 5,368,959 cases in 2017. Among EU-5 countries, UK had the highest number of prevalent cases with approximately 1,183,148 cases, followed by Germany with approximately 485,346 cases in 2017. Italy had the least number of prevalent cases, while in Japan, the prevalent population of Treatment-Resistant Depression was found to be approximately 639,951.

Treatment-Resistant Depression Report Insights
  • The report covers a descriptive overview of the Treatment-Resistant Depression, explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Treatment-Resistant Depression in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.
Treatment-Resistant Depression Report Key Strengths
  • 10-Year Forecast
  • 7MM Coverage
  • Diagnosed Prevalent Patient Pool of Treatment-Resistant Depression
  • Gender-Specific Diagnosed Patient Pool of Treatment-Resistant Depression
  • Age-Specific Diagnosed Patient Pool of Treatment-Resistant Depression
Treatment-Resistant Depression Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
Key Benefits
  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by type
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Treatment-Resistant Depression: Patient Overview at a Glance
2.1. Patient Share (%) Distribution of Treatment-Resistant Depression in 2017
2.2. Patient Share (%) Distribution of Treatment-Resistant Depression in 2028

3. Disease Overview: Treatment-Resistant Depression
3.1. Introduction
3.2. Signs and Symptoms
3.3. Causes and Risk factors
3.4. Pathophysiology of depression
3.5. Genetic Basis of Major Depressive Disorder
3.6. Treatment Refractory Depression: Staging
3.7. Diagnosis
3.7.1. The Diagnostic and Statistical Manual of Mental Disorders (DSM)
3.7.2. DSM-IV-TR Criteria for Major Depressive Disorder
3.7.3. DSM-IV-TR criteria for severity/psychotic/remission specifiers for current (or most recent) Major Depressive Episode
3.7.4. DSM-V: Diagnostic Criteria - Major depressive disorder
3.7.5. Diagnostic Features
3.7.6. Differential Diagnosis
3.7.7. Diagnostic Criteria of Major Depressive Disorder According to ICD-10

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Diagnosed Prevalent Patient Population of Treatment-Resistant Depression
4.3. Country Wise-Epidemiology of Treatment-Resistant Depression
4.4. United States
4.4.1. Assumptions and Rationale
4.4.2. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the United States
4.4.3. Gender-Specific Cases of Treatment-Resistant Depression in the United States
4.4.4. Age-Specific Cases of Treatment-Resistant Depression in the United States
4.5. EU5
4.5.1. Assumptions and Rationale
4.6. Germany
4.6.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Germany
4.6.2. Gender-Specific Cases of Treatment-Resistant Depression in Germany
4.6.3. Age-Specific Cases of Treatment-Resistant Depression in Germany
4.7. France
4.7.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in France
4.7.2. Gender-Specific Cases of Treatment-Resistant Depression in France
4.7.3. Age-Specific Cases of Treatment-Resistant Depression in France
4.8. Italy
4.8.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy
4.8.2. Gender-Specific Cases of Treatment-Resistant Depression in Italy
4.8.3. Age-Specific Cases of Treatment-Resistant Depression in Italy
4.9. Spain
4.9.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain
4.9.2. Gender-Specific Cases of Treatment-Resistant Depression in Spain
4.9.3. Age-Specific Cases of Treatment-Resistant Depression in Spain
4.10. United Kingdom
4.10.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in United Kingdom
4.10.2. Gender-Specific Cases of Treatment-Resistant Depression in the United Kingdom
4.10.3. Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom
4.11. Japan
4.11.1. Assumptions and Rationale
4.11.2. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan
4.11.3. Gender-Specific Cases of Treatment-Resistant Depression in Japan
4.11.4. Age-Specific Cases of Treatment-Resistant Depression in Japan

5. Unmet Needs

6. Market Drivers

7. Market Barriers

8. Appendix
8.1. Report Methodology

9. Capabilities

10. Disclaimer

11. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll